Robert Zielinski

2.6k total citations
41 papers, 370 citations indexed

About

Robert Zielinski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Robert Zielinski has authored 41 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Robert Zielinski's work include Prostate Cancer Treatment and Research (9 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Robert Zielinski is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Robert Zielinski collaborates with scholars based in Australia, Canada and United Kingdom. Robert Zielinski's co-authors include Kim N., Robert L. Dunbrack, Bernhard J. Eigl, Kate M. Gunn, Michael S. Sabel, Terry Boyle, D. Höhn, Phyllis Butow, Ilse Mesters and Stephen B. Edge and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Robert Zielinski

39 papers receiving 363 citations

Peers

Robert Zielinski
Tomoko Seki Japan
Judith Youngson United Kingdom
Eric C. Nelson United States
Emmanuel Abu United Kingdom
Denise Landry Canada
Irmeli Lindström Finland
Erin A. Blake United States
Jiajia Huang China
Claudia Spix Germany
Monika Rucińska Poland
Tomoko Seki Japan
Robert Zielinski
Citations per year, relative to Robert Zielinski Robert Zielinski (= 1×) peers Tomoko Seki

Countries citing papers authored by Robert Zielinski

Since Specialization
Citations

This map shows the geographic impact of Robert Zielinski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Zielinski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Zielinski more than expected).

Fields of papers citing papers by Robert Zielinski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Zielinski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Zielinski. The network helps show where Robert Zielinski may publish in the future.

Co-authorship network of co-authors of Robert Zielinski

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Zielinski. A scholar is included among the top collaborators of Robert Zielinski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Zielinski. Robert Zielinski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Crumbaker, Megan, Mitchell G. Lawrence, Leonard D. Goldstein, et al.. (2025). A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).. Journal of Clinical Oncology. 43(5_suppl). 218–218.
2.
3.
Davis, Ian D., Robert Zielinski, Alastair Thomson, et al.. (2024). Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).. Journal of Clinical Oncology. 42(16_suppl). 5079–5079. 3 indexed citations
4.
Klein, Oliver, Matteo S. Carlino, Michelle Brown, et al.. (2024). 282P Nivolumab and ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancer. Annals of Oncology. 35. S119–S119. 2 indexed citations
5.
Lim, Annette M., Mathias Bressel, Jenny Lee, et al.. (2024). Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. The Medical Journal of Australia. 220(2). 80–90. 8 indexed citations
6.
7.
Segelov, Eva, Wei Wang, Gwo Fuang Ho, et al.. (2023). LBA29 Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial. Annals of Oncology. 34. S1269–S1269. 2 indexed citations
8.
9.
Dougherty, Sean C., et al.. (2023). Refractory Immune Thrombocytopenic Purpura with Abdominal Splenosis: A Complex Case. SHILAP Revista de lepidopterología. 2023. 1–7. 1 indexed citations
10.
Zielinski, Robert, et al.. (2023). Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy. SHILAP Revista de lepidopterología. 16(1). 188–193. 3 indexed citations
11.
Webster, Emma, et al.. (2022). ‘The best thing since sliced bread’: Patient experiences of teleoncology in western NSW. Australian Journal of Rural Health. 31(1). 90–97. 7 indexed citations
12.
Butow, Phyllis, Ilse Mesters, Terry Boyle, et al.. (2021). Psychosocial well-being and supportive care needs of cancer patients and survivors living in rural or regional areas: a systematic review from 2010 to 2021. Supportive Care in Cancer. 30(2). 1021–1064. 51 indexed citations
13.
Ooi, Soo Liang, Sok Cheon Pak, Peter S. Micalos, et al.. (2020). Rice bran arabinoxylan compound and quality of life of cancer patients (RBAC-QoL): Study protocol for a randomized pilot feasibility trial. Contemporary Clinical Trials Communications. 19. 100580–100580. 4 indexed citations
14.
Zielinski, Robert, et al.. (2017). Pseudoprogression Associated with Clinical Deterioration and Worsening Quality of Life in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 13(1). e1–e2. 5 indexed citations
15.
Zielinski, Robert, Arun Azad, Kim N., & Scott Tyldesley. (2014). Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer. Canadian Urological Association Journal. 8(7-8). 520–520. 4 indexed citations
16.
Zielinski, Robert, Bernhard J. Eigl, & Kim N.. (2013). Targeting the Apoptosis Pathway in Prostate Cancer. The Cancer Journal. 19(1). 79–89. 47 indexed citations
17.
Gallagher, Gabrielle, Yifei Huang, Robert Zielinski, Shin Morita, & Stephen N. Hunyor. (2007). Effect of Direct Cardiac Compression on Left Ventricular Axial Dynamics in Sheep. ASAIO Journal. 53(3). 292–297. 2 indexed citations
18.
Jiang, Shucui, Caleb C. J. Zavitz, Jian Wang, et al.. (2006). Non-adenine based purines accelerate wound healing. Purinergic Signalling. 2(4). 651–661. 8 indexed citations
19.
Gallagher, Gabrielle, Yifei Huang, Shin Morita, Robert Zielinski, & Stephen N. Hunyor. (2006). Efficacy and Mechanisms of Biventricular and Left/Right Direct Cardiac Compression in Acute Heart Failure Sheep. Artificial Organs. 31(1). 39–44. 9 indexed citations
20.
Sabel, Michael S., Ellis Levine, Thelma C. Hurd, et al.. (2001). Is MUGA Scan Necessary in Patients With Low-Risk Breast Cancer Before Doxorubicin-Based Adjuvant Therapy?. American Journal of Clinical Oncology. 24(4). 425–428. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomoko Seki Breakdown of academic impact, for papers by Judith Youngson Breakdown of academic impact, for papers by Eric C. Nelson Breakdown of academic impact, for papers by Emmanuel Abu Breakdown of academic impact, for papers by Denise Landry Breakdown of academic impact, for papers by Irmeli Lindström Breakdown of academic impact, for papers by Erin A. Blake Breakdown of academic impact, for papers by Jiajia Huang Breakdown of academic impact, for papers by Claudia Spix Breakdown of academic impact, for papers by Monika Rucińska
Rankless by CCL
2026